Related references
Note: Only part of the references are listed.Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappa B and T-cell receptor pathways
M. B. Wozniak et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine
Saman Hewamana et al.
CLINICAL CANCER RESEARCH (2008)
Inhibition of IκB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-κB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents
Aurore Sors et al.
CLINICAL CANCER RESEARCH (2008)
Active roles for inhibitory κB kinases α and β in nuclear factor-κB-mediated chemoresistance to doxorubicin
Brian K. Bednarski et al.
MOLECULAR CANCER THERAPEUTICS (2008)
RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin
Jing Mi et al.
MOLECULAR THERAPY (2008)
Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-α resistance
Donghao Shang et al.
CANCER SCIENCE (2007)
SOCS1 silencing enhances antitumor activity of type IIFNs by regulating apoptosis in neuroendocrine tumor cells
Kathrin Zitzmann et al.
CANCER RESEARCH (2007)
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products
Ajaikumar B. Kunnumakkara et al.
CANCER RESEARCH (2007)
Continuous delivery of human type I interferons (α/β) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model
Reuben Benjamin et al.
BLOOD (2007)
The NF-kappa B pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
D Cilloni et al.
LEUKEMIA (2006)
Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta
CJ Streck et al.
CANCER GENE THERAPY (2006)
Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models
AM Davidoff et al.
MOLECULAR THERAPY (2005)
Transcription-based prediction of response to IFN beta using supervised computational methods
SE Baranzini et al.
PLOS BIOLOGY (2005)
Mechanisms of disease: Acute lymphoblastic leukemia
C Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Transcriptional response of T cells to IFN-α:: Changes induced in IFN-α-sensitive and resistant cutaneous T cell lymphoma
L Tracey et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2004)
Clonal relationship in multifocal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue (MALT)
B Alpen et al.
ANNALS OF HEMATOLOGY (2004)
Restriction of neuroblastoma angiogenesis and growth by interferon-α/β
CJ Streck et al.
SURGERY (2004)
Development of the proteasome inhihitor Veleade((TM)) (Bortezomib)
J Adams et al.
CANCER INVESTIGATION (2004)
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements
CH Pui et al.
LEUKEMIA (2003)
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region
CH Pui et al.
LANCET (2002)
Interferon-α resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells
A Brinckmann et al.
BRITISH JOURNAL OF CANCER (2002)
IFNα/β promotes cell survival by activating NF-κB
CH Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
